160 results about "Immunoconjugate" patented technology

The present invention relates to antibodies that bind AXL. The present invention relates to anti-AXL antibodies, immunoconjugates, compositions, and methods of using such anti-AXL antibodies, immunoconjugates, or compositions to treat cancer.

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising the IL-2 mutant protein, nucleic acids encoding the IL-2 mutant protein, the dimer and the immunoconjugate, and a vector and host cell comprising the nucleic acid. Further provided are methods for preparing the IL-2 mutant protein, the fusion protein, the dimer and the immunoconjugate, a pharmaceutical composition containing same, and the therapeutic use thereof.

Provided are an anti-CLDN18.2 antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding the same, an immunoconjugate, bispecific molecule, chimeric antigen receptor and pharmaceutical composition comprising the same. The antibody or antigen-binding fragment thereof is used for preventing and / or treating a tumor.

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.

This invention relates to antigen-binding molecules that specifically bind to ALPPL2 and / or ALPP but not ALPL or ALPI. The invention also relates to pharmaceutical compositions, immunoconjugates, and chimeric antigen receptors comprising said antigen-binding molecules. Furthermore, the invention relates to methods for reducing the expression or activity of ALPPL2 in cancer cells, and methods for treating cancer in subjects.

Disclosed are anti-CD3 single domain antibodies and uses thereof. Also provided is a molecule, e.g., a bi-specific or multi-specific molecule, or an immunoconjugate, containing the single domain antibody. Additionally provided are nucleic acids encoding the antibody molecules, as well as vectors and host cells comprising the nucleic acids.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.

The present invention relates to a novel interleukin-2 (IL-2) mutant protein. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.

The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

This invention provides an antibody that binds to the Frizzled receptor, particularly an antibody that binds to the Frizzled receptor 4-cysteine-rich domain, and a method for using the same. [Solution] The present invention provides an isolated antibody and immunoconjugate that specifically bind to the Frizzled receptor (FZD) 4 cysteine-rich domain (CRD), comprising a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises complementarity-determining regions CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises complementarity-determining regions CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequence of the CDR comprises or consists of a sequence selected from a specific group of sequences.

Provided herein are anti-IL-4R [alpha] antibodies or antigen-binding fragments thereof, and to polynucleotides encoding the antibody or antigen-binding protein constructs, as well as expression vectors and host cells comprising the same. Also provided are immunoconjugates, pharmaceutical compositions and medicaments, as well as their use in treating diseases or disorders.

The present application belongs to the field of disease treatment and immunology, in particular, the present application discloses an antibody or antigen-binding fragment thereof against CD73, a nucleic acid molecule encoding the same, an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the same, and the use thereof for enhancing an immune response and / or treating a tumor.

The invention relates to a bispecific antibody targeting HBsAg and DEC-205, and further relates to an antibody coupling medicine containing the antibody as well as a preparation method and application of the antibody coupling medicine.

The present disclosure relates to methods of treating gastroesophageal cancer in a patient, said methods comprising administering to the patient: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) a fluoropyrimidine; and (c) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is from 1 to 10.

Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Provided are novel anti-sTn antibodies and immunoconjugates thereof as well as methods of using such anti-sTn antibodies and immunoconjugates to treat cancer.

The present application relates to an antigen-binding protein targeting CD38 and the use thereof, and specifically relates to an isolated antigen-binding protein, which is capable of binding to CD38. The antigen-binding protein contains at least one CDR in an antibody heavy chain variable region. Further provided in the present application are a chimeric antigen receptor containing the antigen-binding protein, a fusion protein, a modified immune cell, an immunoconjugate, a pharmaceutical composition, a nucleic acid encoding the antigen-binding protein, a vector containing the nucleic acid molecule, and a cell containing the vector. Further provided in the present application is the use of the antigen-binding protein in the prevention and / or treatment of a disease.

The present invention relates to PD-1:PD-L1 non-blocking immunoconjugates comprising an IL-2 polypeptide that provides a biased signal to the dimeric IL-2 receptor and a PD-1 targeting domain, and their use to treat cancer.

This disclosure describes methods and drug therapies for treating or preventing various health conditions, including cancer. The methods and therapies of the present disclosure comprise antibody-based therapies that functionally increase antibody binding to target antigens. Specifically, the antibody-based therapies increase the copy number of an antigen by utilizing at least a pair of differing antibodies directed at non-overlapping epitopes of the same antigen for effectively delivering payloads to a target cell. Each differing antibody may be conjugated to the same or a differing payload. The antibody-based therapy may use proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat conditions, such as cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

Provided in the present invention are an antibody binding to FOLR1, a drug containing same, and a use thereof. The antibody for FOLR1 can specifically bind to FOLR1 and be internalized by cells, and can be used for inhibiting diseases associated with FOLR1 expression (including overexpression) or affected by FOLR1 function, such as tumors. The present invention also comprises an immunoconjugate containing the antibody.

The present application relates to DLL3 antigen binding proteins and uses thereof, in particular to an isolated antigen binding protein capable of binding DLL3, said antigen binding protein comprising an antibody heavy chain variable region VH and VL, said VH and VL comprising at least one CDR. The present application also provides a chimeric antigen receptor comprising said DLL3 antigen binding protein, a modified immune cell, an immunoconjugate, a pharmaceutical composition, a pharmaceutical combination, a nucleic acid encoding said antigen binding protein, a vector comprising said nucleic acid molecule, a cell comprising said vector. The present application also provides the use of said antigen binding protein in preventing and / or treating a disease.

The present disclosure provides methods of treating neuroendocrine cancers using immunoconjugates comprising an antibody that specifically binds hCEACAM5, in particular hCEACAM5.